Altus Infusion now offering managed care services

December 09, 2013

As a value-added service to our clients, Altus Infusion can analyze provider managed care agreements and engage in contract negotiation on your behalf.

Humana authorization requirements for 2014

Please check the newly published list of drugs that require prior authorization in 2014. These changes will go into effect on January 18. For the complete listing of drugs included in this new policy as well as other Humana News, please go to the following web address:
https://www.humana.com/provider/medical-providers/education/whats-new/

For drug specific authorization forms please go the following web address:

More assistance funds available for Actemra and Rituxan patients

Assistance programs for Actemra and Rituxan have increased to $10,000 annually with a $5 patient responsibility. The change was made effective November 1, 2013.

New Mastercards for Cimzia patients

As a result of UCB changing its credit card vendor, Cimzia patients will be issued new cards. Providers will be required to re-register their terminals with new control card information.

Savient files for bankruptcy

The manufacturer of Krystexxa, Savient, announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code. Savient expects to continue normal business operations as it moves through this process.

Foundation funding update

As of December 2, PANF has no current funding available for the following diagnosis:

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Postmenopausal Osteoporosis

PANF has funding available to patients diagnosed with Senile Osteoporosis.

HAWF has funding for Systemic Lupus and Chronic Gout. There is no current funding for:

  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Psoriatic Arthritis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Postmenopausal Osteoporosis